Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase Ia Study of MST-931 in Healthy Adult Subjects
Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd.
Summary
A Phase 1a, randomized, double-blind study of MST-931 in healthy participants. The purpose of this research is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous dose of MST-931 given to healthy participants. MST-931 is a monoclonal antibody.
Official title: A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MST-931 in Healthy Adult Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2026-11-30
Completion Date
2027-07-30
Last Updated
2026-11-03
Healthy Volunteers
Yes
Conditions
Interventions
MST-931
MST-931 is a proprietary monoclonal antibody developed by Mabsoft Therapeutics.
MST-931 Placebo
Matching placebo for MST-931
Locations (1)
Q-Pharm Pty Ltd
Herston, Queensland, Australia